Abstract 2154P
Background
The role of lipid levels in the development and outcomes of cancer patients remains unclear in the literature. In this study, we aimed to analyze whether there is a relationship between total cholesterol levels and the survival of hospitalized cancer patients.
Methods
This retrospective observational study included patients admitted to the Medical Oncology Hospitalization Unit at La Paz University Hospital between September 2018 and January 2020. Total cholesterol levels, tumor type, treatment received, and mortality were analyzed.
Results
A total of 839 patients were included, with no differences in gender distribution. The most frequent tumor was lung (20.7%), followed by digestive tumors, including colorectal, esophagogastric, pancreatobiliary, or hepatic (33.4%), and breast (11.4%). The majority of patients were receiving active cancer-specific treatment, with chemotherapy (51.5%) or targeted treatments (18.6%) at the time of admission. At the end of the median follow-up period (31,8 months), 615 deaths had occurred (78.9%). The median overall survival (OS), regardless of tumor type, was 199 days. Having low total cholesterol values (less than 150 mg/dL) increased the risk of mortality by 25.9% compared to having physiological levels (150-200 mg/dL) (p=0.016, CI95% 1.045, 1.518)) with a Hazard Ratio of 1.259. Having high total cholesterol values (above 200 mg/dL) increased the risk of mortality by 30.6% compared to having physiological levels (p=0.036, CI95%(1.017, 1.677)) with an HR of 1.306.
Conclusions
To date, the majority of studies indicate that elevated cholesterol levels in patients with advanced cancer are associated with a higher risk of mortality, both due to a higher burden of comorbidity and the potential effects of cholesterol on oncogenic pathways. On the other hand, low cholesterol levels, possibly reflecting a significant metabolic dysregulation during cachexia, seem to be linked to a worse prognosis as well. Although the mechanisms by which high or low cholesterol levels increase the risk of mortality may differ, their incorporation into prognostic scores can contribute to a more accurate estimation of prognosis in advanced patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2194P - Prospective observational study of physical activity measurement using wearable device as an alternative to ECOG PS in patients with advanced lung cancer
Presenter: Kentaro Ito
Session: Poster session 07
Resources:
Abstract
2195P - Targeted gene editing with CRISPR for the treatment of pleural mesothelioma
Presenter: Rodrigo Dominic Cerqueda
Session: Poster session 07
2196P - PET-CT detects response to treatment with ipilimumab and nivolumab in malignant mesothelioma far better than CT
Presenter: Daniel C. Christoph
Session: Poster session 07
2197P - Prognostic value of 18F-FDG-PET for patients with malignant pleural mesothelioma treated with double immunotherapy
Presenter: Solfrid Thunold
Session: Poster session 07
2198P - Clinicopathologic characteristics and outcomes to immune checkpoint inhibitor therapy in patients with HER2-altered metastatic non-small cell lung cancer
Presenter: Maisam Makarem
Session: Poster session 07
2199P - Immunohistochemical identification of clinical subtypes and potential therapeutic vulnerabilities of lung carcinoids based on multi-omic analysis
Presenter: Jules Derks
Session: Poster session 07
2200P - Spatiotemporal distribution of mediastinal neoplasms: A multi-center, hospital-based, systematic analysis
Presenter: Yu Jiang
Session: Poster session 07
2201P - Malignant pleural mesothelioma (MPM)-specific DNA methylation patterns in patients using liquid biopsies
Presenter: Sabine Schmid
Session: Poster session 07
2202P - Large cell neuroendocrine carcinoma (LCNEC) subtyping based on NEUROD1, ASCL1, POU2F3 and YAP1 expression
Presenter: Frank Heijboer
Session: Poster session 07
2203P - Uncovering prognostic transcriptomic differences in epithelioid malignant pleural mesothelioma
Presenter: Mario Occhipinti
Session: Poster session 07